GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Profitability Rank

Soligenix (Soligenix) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Soligenix Profitability Rank?

Soligenix has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Soligenix's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Soligenix's Piotroski F-Score is 2.


Competitive Comparison of Soligenix's Profitability Rank

For the Biotechnology subindustry, Soligenix's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Soligenix's Profitability Rank falls into.



Soligenix Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Soligenix has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Soligenix's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2.131 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Soligenix has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Soligenix Profitability Rank Related Terms

Thank you for viewing the detailed overview of Soligenix's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (Soligenix) Business Description

Traded in Other Exchanges
N/A
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
Timothy R. Cote director 3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube officer: CMO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber director, officer: Chairman, CEO and President 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino officer: Chief Financial Officer 100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini officer: CSO 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson director, 10 percent owner 3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza other: Former 10% Owner VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza other: Former 10% Owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144